Your GGT Is 38 and Your Doctor Said 'Normal' — That Number Is the Earliest Warning Sign of Fatty Liver and Cardiovascular Mortality You Will Get

Most people get a comprehensive metabolic panel once a year. Most of those panels include something called GGT, or gamma-glutamyl transferase. Most patients have never heard of it. Most doctors glance at it, see a number under 55, and move on without comment.

That is a problem. Because GGT is one of the most prognostic markers on a routine blood panel — and the standard reference range is built on hospital lab populations, not on outcomes data. By the time your GGT crosses the "abnormal" threshold of 55 IU/L, you have already had years of silent oxidative damage, almost-certain fatty liver involvement, and a measurably elevated risk of cardiovascular death.

If you are a high-functioning professional in your 40s or 50s, GGT in the 30 to 55 range is one of the loudest early-warning lights you will ever get from a single blood draw. And almost no one is listening to it.

What GGT actually measures

Gamma-glutamyl transferase is an enzyme that lives primarily in the liver, but also in the kidneys, pancreas, and the brush border of the small intestine. Its job is to transfer gamma-glutamyl groups from one peptide to another — specifically, it is the gatekeeper enzyme for the glutathione recycling pathway.

Here is the key fact most internists do not internalize: GGT goes up when the liver is under oxidative stress, not just when it is structurally damaged. ALT and AST go up when liver cells are dying. GGT goes up when liver cells are working overtime to detoxify, recycle glutathione, and handle a chronic chemical burden — alcohol, fructose, environmental toxins, medications, visceral fat, insulin resistance.

This is why GGT is sometimes called the "canary in the coal mine" for liver and metabolic health. It rises before structural damage. It rises before ALT and AST. It rises before fatty liver shows up on ultrasound.

And it rises in lockstep with cardiovascular mortality risk, even in people whose other liver markers look pristine.

The reference range is broken

LabCorp lists the GGT reference range as roughly 0–55 IU/L for men and 0–38 IU/L for women, depending on the assay. The "<55" ceiling for men has been functionally unchanged for decades. The problem is that those ranges are derived from the statistical distribution of values in the general lab-using population — which now skews heavily toward metabolic dysfunction, fatty liver, and chronic low-grade oxidative stress.

In other words, "normal" GGT today reflects what is common, not what is healthy.

The outcomes data tells a different story. The Bruneck Study followed roughly 6,300 healthy adults for years and found that even modest GGT elevations within the "normal" range tracked tightly with future cardiovascular events. A widely cited Framingham follow-up published in Circulation (Ruttmann et al., 2005) showed that GGT was an independent predictor of all-cause and cardiovascular mortality in a population free of clinical liver disease. A 2014 meta-analysis (Kunutsor et al., International Journal of Cardiology) pooled data across more than 600,000 participants and found a graded, dose-response relationship between GGT and coronary heart disease incidence — with risk beginning to climb well below the conventional upper limit.

The Vital Statistics of American Health surveys have shown that GGT in the highest quartile of "normal" carries roughly double the all-cause mortality risk of GGT in the lowest quartile, even after adjusting for alcohol use, body mass index, and traditional cardiovascular risk factors.

Translation: a GGT of 38 in a non-drinking 48-year-old is not "normal." It is a signal that the liver is already working harder than it should be, and the cardiovascular system is going to be paying the bill for years to come.

Why "optimal" is under 20

Functional medicine and longevity-focused clinicians have been quietly converging on a much tighter optimal range — generally under 20 IU/L for both men and women, with some practitioners pushing for under 15 in younger patients.

The reasoning is mechanistic, not arbitrary:

• Glutathione status. Intracellular glutathione is the master antioxidant. When glutathione is being heavily consumed or recycled, GGT activity rises at the cell surface to scavenge the precursor amino acids needed to make more. A GGT under 20 generally reflects a system that is not under chronic oxidative pressure.
• Hepatic fat infiltration. Multiple imaging studies have shown that liver fat fraction on MR spectroscopy correlates with GGT even at values well within the "normal" range. By the time GGT crosses 40, the probability of non-alcoholic fatty liver disease (now reclassified as MASLD — metabolic dysfunction-associated steatotic liver disease) is meaningfully elevated, often above 50% in middle-aged adults.
• Insulin signaling. Elevated GGT is one of the strongest single-marker predictors of incident type 2 diabetes in prospective cohorts — sometimes a stronger predictor than fasting glucose itself, particularly in the 30–55 range where doctors are not looking.
• Endothelial function. Oxidative stress damages the vascular endothelium. GGT itself can catalyze pro-oxidant reactions inside arterial plaque. Higher GGT, more oxidized LDL, more plaque progression, more events.

When you stack those mechanisms, an "optimal" range of under 20 is not a wellness-influencer fantasy. It is a defensible synthesis of the survival data, the imaging data, and the underlying biochemistry.

What pushes GGT up — and what most doctors miss

Most clinicians have one mental model for elevated GGT: alcohol. If the patient does not drink heavily, the elevation is dismissed as idiopathic or "your normal."

That model is incomplete. In a sober, non-medicated executive in their 40s or 50s, the most common drivers of a GGT in the 30s and 40s are not alcohol. They are:

• Visceral adiposity and insulin resistance. Even at a normal BMI, the "thin outside, fat inside" phenotype — with substantial intra-abdominal and intrahepatic fat — drives GGT into the upper "normal" range. Waist-to-height ratio above 0.50 is a tighter predictor than BMI.
• Fructose load. High fructose intake (sweetened beverages, agave, fruit juices, the back-end of processed food labels) is metabolized almost exclusively in the liver and is one of the most potent drivers of de novo lipogenesis and hepatic oxidative stress.
• Environmental and chemical exposure. Solvents, pesticides, certain plasticizers, and a long list of common medications (statins, NSAIDs, anti-epileptics, some antibiotics) all increase GGT as the liver upregulates detoxification. Industrial exposures or even chronic prescription polypharmacy in older patients can quietly push GGT up.
• Iron overload, even subclinical. Elevated ferritin with elevated GGT is a classic functional pattern for hepatic iron stress and is associated with insulin resistance independent of true hereditary hemochromatosis. (See Dispatch Article 14 on ferritin for the full picture.)
• Subclinical biliary stasis. GGT, alongside alkaline phosphatase, is sensitive to cholestasis. A sluggish biliary system — sometimes driven by suboptimal bile acid recycling, certain supplements, or post-cholecystectomy adaptation — can lift GGT without any structural pathology.
• Smoking and chronic inflammation. Both increase systemic oxidative stress and consistently push GGT up by several IU/L on average.

The clinical pattern that should set off alarms is the combination most often seen in high-achievers: a GGT in the 30–50 range, ferritin above 200, triglycerides above 100, and an HDL drifting under 50. That cluster is a metabolic syndrome signature, even if the fasting glucose and HbA1c still look fine.

The cardiovascular link is mechanistic, not statistical

It is tempting to read the GGT–cardiovascular literature as a confounding artifact: elevated GGT just tracks with metabolic syndrome, and metabolic syndrome is the real driver. But multiple studies have shown that GGT is an independent predictor even after adjusting for traditional risk factors, lipids, blood pressure, and insulin resistance.

The mechanistic explanation is straightforward. GGT is enzymatically active inside atherosclerotic plaque. It catalyzes the formation of reactive oxygen species in the immediate vicinity of LDL particles trapped in the arterial wall. Higher local GGT activity, more LDL oxidation, more foam cell formation, faster plaque progression.

In other words, GGT is not just a passive marker of systemic stress. Within the artery wall itself, it appears to be an active participant in the oxidation chemistry that drives plaque growth and instability.

A reading of 38 in a 50-year-old who drinks twice a month is not telling you the patient has liver disease. It is telling you the patient has a quietly accelerated rate of LDL oxidation and is on a trajectory toward earlier, more rapid plaque progression than their lipid panel would suggest.

What to actually do with the number

If GGT comes back above 20, the right response is not to repeat the test in a year. It is to investigate the upstream drivers.

A reasonable functional workup includes:

1. Repeat the test fasted, no alcohol for at least seven days. A single elevation can reflect a recent stressor. A persistent elevation across two clean draws is the real signal.
2. Pair with ferritin, fasting insulin, triglycerides, HDL, ALT, and AST. GGT in isolation tells you "stress." GGT with elevated ferritin and triglycerides plus normal ALT/AST tells you "metabolic and oxidative" — the visceral fat, fructose, insulin resistance, oxidative-stress cluster. GGT with elevated ALT/AST tells you to look at structural liver involvement and consider imaging.
3. Get a fasting insulin and HOMA-IR. Most elevated GGT in non-drinkers is metabolic. If fasting insulin is above roughly 7 µIU/mL, that is the lever.
4. Consider a liver elastography or MR-PDFF imaging study in patients with persistent GGT elevation plus a metabolic pattern. Ultrasound is not sensitive enough at this stage; FibroScan (transient elastography) is cheap and far more informative.
5. Check waist-to-height ratio, not just BMI. A ratio above 0.5 in the presence of "normal" GGT in the 30s is the visceral-fat phenotype.

The therapeutic levers are the same levers that improve every other metabolic marker on the panel: substantial fructose reduction, time-restricted eating, resistance training to build muscle mass, sleep that actually allows the liver its overnight processing window, and intentional management of any meaningful alcohol intake. The liver responds to these inputs quickly — meaningful GGT reductions within 8 to 12 weeks are common when the underlying inputs change.

Supplemental support — N-acetylcysteine, choline, betaine, milk thistle silymarin, omega-3s — has reasonable evidence for supporting hepatic antioxidant capacity, but none of those substitute for fixing the inputs. They are adjuncts to lifestyle change, not workarounds.

The bottom line

GGT is one of the cheapest, most prognostic, and most ignored markers in standard medicine. The "normal" range is a relic of population-distribution statistics from an era when chronic metabolic dysfunction was less universal than it is now. The outcomes data, the imaging data, and the underlying biochemistry all converge on the same conclusion: optimal GGT is under 20, the 20–40 zone is an early warning, and the 40–55 "still normal" zone is a quiet trajectory toward fatty liver and earlier cardiovascular events.

If your last comprehensive metabolic panel showed a GGT in the 30s or 40s and your doctor said you were fine, you are not fine. You are early. That is the most useful information a single blood draw can ever give you — provided someone is willing to read it.

The point of running a comprehensive panel is not to confirm you are "in range." It is to find the markers that are telling you something is upstream of trouble. GGT, for most adults over 40, is exactly that marker. It deserves the attention.

This article is part of the 1836 Peptide Dispatch research series on under-ordered, high-information biomarkers. For the full marker series, see prior articles on uric acid, ferritin, vitamin D, homocysteine, thyroid TSH, cortisol, testosterone, ApoB, growth hormone, NAD, and insulin resistance.

Educational content only. Not medical advice. Reference ranges and clinical interpretation should always be done in the context of a complete clinical picture by a qualified clinician.